The Current Ratio as of September 2024 (TTM) for Insmed Incorporated (INSM) is 2.71

According to Insmed Incorporated’s latest financial reports and current stock price. The company's current Current Ratio is 2.71. This represents a change of -18.85% compared to the average of 3.33 of the last 4 quarters.

Insmed Incorporated (INSM) Historical Current Ratio (quarterly & annually)

How has INSM Current Ratio performed in the past?

The mean historical Current Ratio of Insmed Incorporated over the last ten years is 7.13. The current 2.71 Current Ratio has changed 3.69% with respect to the historical average. Over the past ten years (40 quarters), INSM's Current Ratio was at its highest in in the March 2018 quarter at 20.01. The Current Ratio was at its lowest in in the March 2024 quarter at 1.80.

Insmed Incorporated (INSM) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Insmed Incorporated Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Insmed Incorporated (INSM) Average Current Ratio

How has INSM Current Ratio performed in the past?

The current Current Ratio of Insmed Incorporated (INSM) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Insmed Incorporated (INSM) Current Ratio vs. Peers

How is INSM’s Current Ratio compared to its peers?

Insmed Incorporated’s Current Ratio is greater than Ascendis Pharma A/S (0.74), less than Apellis Pharmaceuticals, Inc. (5.08), greater than BeiGene, Ltd. (1.98), less than Akero Therapeutics, Inc. (24.89), less than Blueprint Medicines Corporation (3.71), less than Cerevel Therapeutics Holdings, Inc. (10.22), less than Avidity Biosciences, Inc. (15.78), less than Revolution Medicines, Inc. (15.42), less than Day One Biopharmaceuticals, Inc. (4.09), less than SpringWorks Therapeutics, Inc. (7.91), less than Keros Therapeutics, Inc. (20.37), less than Janux Therapeutics, Inc. (57.34), less than Fennec Pharmaceuticals Inc. (8.02), less than Edgewise Therapeutics, Inc. (30.24), less than Harmony Biosciences Holdings, Inc. (3.13), less than Halozyme Therapeutics, Inc. (7.41), less than Agios Pharmaceuticals, Inc. (10.09), less than Ultragenyx Pharmaceutical Inc. (3.54),

Build a custom stock screener for Insmed Incorporated (INSM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Insmed Incorporated using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Insmed Incorporated (INSM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Insmed Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.